Martin Reck, MD, PhD, on Selecting Immunotherapy
Posted: Tuesday, November 14, 2017
Although nivolumab, for instance, may be prescribed for patients with low or no PD-L1 expression, how likely are you to select immunotherapy for such patients?
Non–Small Cell Lung Cancer Coverage from Every Angle
